Interferon is more effective in patients with the following conditions: (1) high levels of alanine aminotransferase (also known as glutamate aminotransferase ALT) and/or aspartate aminotransferase (also known as glutamate aminotransferase AST) before treatment (this is very important, in general, the efficacy of interferon is proportional to the serum aminotransferase level, that is, if the aminotransferase is normal before treatment, interferon is often ineffective or has poor efficacy); conversely, if the aminotransferase level is high before treatment, the efficacy is generally better; (2) low viral load, HBVDNA <2×108 copies/ml; (3) female; (4) hepatitis B patients with the following conditions (2) low viral load, HBVDNA <2×108 copies/ml; (3) female; (4) short duration of disease; (5) non-maternal-to-child transmission; (6) heavy inflammatory necrosis of liver tissue and light fibrosis (we need to do liver biopsy to know, most patients do not accept liver biopsy, this article is for reference only); (7) good compliance with treatment (8) good compliance with treatment; (8) no hepatitis C virus (HCV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV) co-infection; (9) HBV gene is type A (most hospitals are not yet equipped to carry out genotyping tests for hepatitis B virus); (10) good response to treatment, i.e. serum HBVDNA is not detectable at 12 or 24 weeks of treatment. Among the above, ALT (and/or AST), HBVDNA level and HBV genotype before treatment are the three important factors to predict the efficacy. In fact, most hospitals are not yet equipped to test for HBV genotype, so the first two of these are the most important.